Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: A Hoosier Oncology Group phase II trial

A. M. Moore, Lawrence Einhorn, D. Estes, R. Govindan, J. Axelson, J. Vinson, T. E. Breen, M. Yu, Nasser Hanna

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Background: Gefitinib has demonstrated activity in patients with non-small cell lung cancer (NSCLC). Clinical trials have not demonstrated a relationship between response to gefitinib and over-expression of the epidermal growth factor receptor (EGFR). Although, EGFR is not over-expressed in small cell lung cancer (SCLC), we postulated that gefitinib might affect tumor growth through other mechanisms. Agents that are active in NSCLC usually are also effective in SCLC. Methods: The primary objective was to assess the clinical control rate: complete response (CR) partial response (PR) and stable disease (SD > 90 days), of gefitinib in patients with chemo-resistant and chemo-sensitive small cell cancers. Eligibility criteria included pathologic proof of a neuroendocrine tumor, especially small cell cancer, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2, prior treatment with one or two prior chemotherapy regimens and adequate end-organ function. Patients received gefitinib, 250 mg p.o. daily until disease progression or intolerable side effects. Results: From April 2003 to March 2004, 19 patients were enrolled. Small cell lung cancer accounted for 18 of the 19 patients and one patient had metastatic Merkel cell carcinoma. Twelve patients (63%) had chemo-sensitive disease, defined as progression greater than three months from completion of prior chemotherapy; 7 (37%) had chemo-refractory disease; 13 (68%) had one prior chemotherapy regimen. Other patient characteristics: mean age 64 years (range 52-79 years); ECOG PS 0/1/2 = 7/9/3, M:F = 9:10. Grade 3 toxicities included: fatigue in three patients (15.8%), pulmonary toxicities in three (15.8%) and one patient (5.3%) each with hyperglycemia or pain. Four patients had grade four toxicities: one patient (5.3%) with fatigue and three patients (15.8%) with dyspnea. There were no patients with grade 3 or 4 rash or diarrhea. Two patients had stable disease (<90 days) and 17 had progressive disease as their best response. This study was a two-stage design and because the continuing criterion for stage one was not met, stage 2 was not performed. Median time to progression (TTP) was 50 days (95% CI = 21-58 days). One year overall survival (OS) was 21% (95% CI = 6-45.6%). Conclusion: Although gefitinib has activity in select patients with NSCLC, this study failed to demonstrate benefit in patients with small cell lung cancer.

Original languageEnglish
Pages (from-to)93-97
Number of pages5
JournalLung Cancer
Volume52
Issue number1
DOIs
StatePublished - Apr 2006

Fingerprint

Neoplasms
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
gefitinib
Epidermal Growth Factor Receptor
Drug Therapy
Fatigue
Merkel Cell Carcinoma
Neuroendocrine Tumors
Exanthema
Hyperglycemia
Dyspnea
Disease Progression
Diarrhea
Clinical Trials
Pain
Lung
Survival
Growth

Keywords

  • Gefitinib
  • Neuroendocrine tumor
  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers : A Hoosier Oncology Group phase II trial. / Moore, A. M.; Einhorn, Lawrence; Estes, D.; Govindan, R.; Axelson, J.; Vinson, J.; Breen, T. E.; Yu, M.; Hanna, Nasser.

In: Lung Cancer, Vol. 52, No. 1, 04.2006, p. 93-97.

Research output: Contribution to journalArticle

Moore, A. M. ; Einhorn, Lawrence ; Estes, D. ; Govindan, R. ; Axelson, J. ; Vinson, J. ; Breen, T. E. ; Yu, M. ; Hanna, Nasser. / Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers : A Hoosier Oncology Group phase II trial. In: Lung Cancer. 2006 ; Vol. 52, No. 1. pp. 93-97.
@article{916468ecbd6344fc90c4e4abd8659dca,
title = "Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: A Hoosier Oncology Group phase II trial",
abstract = "Background: Gefitinib has demonstrated activity in patients with non-small cell lung cancer (NSCLC). Clinical trials have not demonstrated a relationship between response to gefitinib and over-expression of the epidermal growth factor receptor (EGFR). Although, EGFR is not over-expressed in small cell lung cancer (SCLC), we postulated that gefitinib might affect tumor growth through other mechanisms. Agents that are active in NSCLC usually are also effective in SCLC. Methods: The primary objective was to assess the clinical control rate: complete response (CR) partial response (PR) and stable disease (SD > 90 days), of gefitinib in patients with chemo-resistant and chemo-sensitive small cell cancers. Eligibility criteria included pathologic proof of a neuroendocrine tumor, especially small cell cancer, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2, prior treatment with one or two prior chemotherapy regimens and adequate end-organ function. Patients received gefitinib, 250 mg p.o. daily until disease progression or intolerable side effects. Results: From April 2003 to March 2004, 19 patients were enrolled. Small cell lung cancer accounted for 18 of the 19 patients and one patient had metastatic Merkel cell carcinoma. Twelve patients (63{\%}) had chemo-sensitive disease, defined as progression greater than three months from completion of prior chemotherapy; 7 (37{\%}) had chemo-refractory disease; 13 (68{\%}) had one prior chemotherapy regimen. Other patient characteristics: mean age 64 years (range 52-79 years); ECOG PS 0/1/2 = 7/9/3, M:F = 9:10. Grade 3 toxicities included: fatigue in three patients (15.8{\%}), pulmonary toxicities in three (15.8{\%}) and one patient (5.3{\%}) each with hyperglycemia or pain. Four patients had grade four toxicities: one patient (5.3{\%}) with fatigue and three patients (15.8{\%}) with dyspnea. There were no patients with grade 3 or 4 rash or diarrhea. Two patients had stable disease (<90 days) and 17 had progressive disease as their best response. This study was a two-stage design and because the continuing criterion for stage one was not met, stage 2 was not performed. Median time to progression (TTP) was 50 days (95{\%} CI = 21-58 days). One year overall survival (OS) was 21{\%} (95{\%} CI = 6-45.6{\%}). Conclusion: Although gefitinib has activity in select patients with NSCLC, this study failed to demonstrate benefit in patients with small cell lung cancer.",
keywords = "Gefitinib, Neuroendocrine tumor, Small cell lung cancer",
author = "Moore, {A. M.} and Lawrence Einhorn and D. Estes and R. Govindan and J. Axelson and J. Vinson and Breen, {T. E.} and M. Yu and Nasser Hanna",
year = "2006",
month = "4",
doi = "10.1016/j.lungcan.2005.12.002",
language = "English",
volume = "52",
pages = "93--97",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers

T2 - A Hoosier Oncology Group phase II trial

AU - Moore, A. M.

AU - Einhorn, Lawrence

AU - Estes, D.

AU - Govindan, R.

AU - Axelson, J.

AU - Vinson, J.

AU - Breen, T. E.

AU - Yu, M.

AU - Hanna, Nasser

PY - 2006/4

Y1 - 2006/4

N2 - Background: Gefitinib has demonstrated activity in patients with non-small cell lung cancer (NSCLC). Clinical trials have not demonstrated a relationship between response to gefitinib and over-expression of the epidermal growth factor receptor (EGFR). Although, EGFR is not over-expressed in small cell lung cancer (SCLC), we postulated that gefitinib might affect tumor growth through other mechanisms. Agents that are active in NSCLC usually are also effective in SCLC. Methods: The primary objective was to assess the clinical control rate: complete response (CR) partial response (PR) and stable disease (SD > 90 days), of gefitinib in patients with chemo-resistant and chemo-sensitive small cell cancers. Eligibility criteria included pathologic proof of a neuroendocrine tumor, especially small cell cancer, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2, prior treatment with one or two prior chemotherapy regimens and adequate end-organ function. Patients received gefitinib, 250 mg p.o. daily until disease progression or intolerable side effects. Results: From April 2003 to March 2004, 19 patients were enrolled. Small cell lung cancer accounted for 18 of the 19 patients and one patient had metastatic Merkel cell carcinoma. Twelve patients (63%) had chemo-sensitive disease, defined as progression greater than three months from completion of prior chemotherapy; 7 (37%) had chemo-refractory disease; 13 (68%) had one prior chemotherapy regimen. Other patient characteristics: mean age 64 years (range 52-79 years); ECOG PS 0/1/2 = 7/9/3, M:F = 9:10. Grade 3 toxicities included: fatigue in three patients (15.8%), pulmonary toxicities in three (15.8%) and one patient (5.3%) each with hyperglycemia or pain. Four patients had grade four toxicities: one patient (5.3%) with fatigue and three patients (15.8%) with dyspnea. There were no patients with grade 3 or 4 rash or diarrhea. Two patients had stable disease (<90 days) and 17 had progressive disease as their best response. This study was a two-stage design and because the continuing criterion for stage one was not met, stage 2 was not performed. Median time to progression (TTP) was 50 days (95% CI = 21-58 days). One year overall survival (OS) was 21% (95% CI = 6-45.6%). Conclusion: Although gefitinib has activity in select patients with NSCLC, this study failed to demonstrate benefit in patients with small cell lung cancer.

AB - Background: Gefitinib has demonstrated activity in patients with non-small cell lung cancer (NSCLC). Clinical trials have not demonstrated a relationship between response to gefitinib and over-expression of the epidermal growth factor receptor (EGFR). Although, EGFR is not over-expressed in small cell lung cancer (SCLC), we postulated that gefitinib might affect tumor growth through other mechanisms. Agents that are active in NSCLC usually are also effective in SCLC. Methods: The primary objective was to assess the clinical control rate: complete response (CR) partial response (PR) and stable disease (SD > 90 days), of gefitinib in patients with chemo-resistant and chemo-sensitive small cell cancers. Eligibility criteria included pathologic proof of a neuroendocrine tumor, especially small cell cancer, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2, prior treatment with one or two prior chemotherapy regimens and adequate end-organ function. Patients received gefitinib, 250 mg p.o. daily until disease progression or intolerable side effects. Results: From April 2003 to March 2004, 19 patients were enrolled. Small cell lung cancer accounted for 18 of the 19 patients and one patient had metastatic Merkel cell carcinoma. Twelve patients (63%) had chemo-sensitive disease, defined as progression greater than three months from completion of prior chemotherapy; 7 (37%) had chemo-refractory disease; 13 (68%) had one prior chemotherapy regimen. Other patient characteristics: mean age 64 years (range 52-79 years); ECOG PS 0/1/2 = 7/9/3, M:F = 9:10. Grade 3 toxicities included: fatigue in three patients (15.8%), pulmonary toxicities in three (15.8%) and one patient (5.3%) each with hyperglycemia or pain. Four patients had grade four toxicities: one patient (5.3%) with fatigue and three patients (15.8%) with dyspnea. There were no patients with grade 3 or 4 rash or diarrhea. Two patients had stable disease (<90 days) and 17 had progressive disease as their best response. This study was a two-stage design and because the continuing criterion for stage one was not met, stage 2 was not performed. Median time to progression (TTP) was 50 days (95% CI = 21-58 days). One year overall survival (OS) was 21% (95% CI = 6-45.6%). Conclusion: Although gefitinib has activity in select patients with NSCLC, this study failed to demonstrate benefit in patients with small cell lung cancer.

KW - Gefitinib

KW - Neuroendocrine tumor

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=33644770041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644770041&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2005.12.002

DO - 10.1016/j.lungcan.2005.12.002

M3 - Article

C2 - 16488055

AN - SCOPUS:33644770041

VL - 52

SP - 93

EP - 97

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -